|
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
EMAST was more frequent in colon cancer than rectal cancer (p=0.033), and associated with MSI-H phenotype (p<0.001), low expression of hMSH3 (p=0.004), and overexpression of thymidylate synthase (p=0.006).
|
27889996 |
2016 |
|
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Tumor TS levels were prospectively evaluated in two adjuvant therapy trials for patients with resected stage II or III colon cancer.
|
27821793 |
2017 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, a comprehensive gene expression analysis at the levels of both transcriptional and post-transcriptional regulation was conducted to identify response markers using human genome array with TS-depleted human colon cancer HCT-C18 (TS-) cells and HCT-C18 (TS+) cells stably transfected with the human TS cDNA expression plasmid.
|
16584549 |
2006 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tamoxifen and gonadal steroids inhibit colon cancer growth in association with inhibition of thymidylate synthase, survivin and telomerase expression through estrogen receptor beta mediated system.
|
11078914 |
2000 |
|
Malignant tumor of colon
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Polymorphism of thymidylate synthase gene associated with its protein expression in human colon cancer.
|
18203297 |
2008 |
|
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Thymidylate synthase messenger RNA expression in plasma from patients with colon cancer: prognostic potential.
|
16609021 |
2006 |
|
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here, we demonstrate that the enhanced HSP90 function and subsequent activation of Src induce expression of TYMS and acquired resistance to 5-FU in colon cancer.
|
26416450 |
2015 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
CTD_human |
Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine.
|
19105824 |
2008 |
|
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this study, we demonstrate that the histone deacetylase inhibitors (HDACi) vorinostat and LBH589 significantly downregulate TS gene expression in a panel of colon cancer cell lines.
|
19384949 |
2009 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thymidylate synthase inhibition triggers apoptosis via caspases-8 and -9 in both wild-type and mutant p53 colon cancer cell lines.
|
12763222 |
2003 |
|
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These features include cellular morphology, expression of colon cancer stem cell markers, expression of survivin and thymidylate synthase and sensitivity to fluorouracil.
|
23674327 |
2013 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
The AUC of TYMS for predicting the efficacy of chemotherapy on colon cancer was 0.831 (95% CI, 0.735-0.926), and both had higher predictive values.
|
31423175 |
2019 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cell death due to thymine (dThd) deficiency, associated with the cytotoxic action of 5-fluorouracil in colon cancer, is regulated in thymidylate synthase-deficient (TS(-)) human colon carcinoma cells via the Fas (CD95, APO-1) death receptor.
|
10744679 |
2000 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
High TS was only found in 9.3% of rectal tumors, but in 29.7% of colon cancers (p=0.0042).
|
23968134 |
2013 |
|
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The effects of fluorouracil (5-FU) and interferon-gamma (IFN-gamma) on the regulation of thymidylate synthase (TS) gene expression were investigated in the human colon cancer H630 cell line.
|
8474431 |
1993 |
|
Malignant tumor of colon
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Although the predictive and prognostic value of thymidylate synthase (TS) expression and gene polymorphism in colon cancer has been widely studied, the results are inconclusive probably because of methodological differences.
|
20966539 |
2010 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
CTD_human |
In both gastric and colon cancers, thymidylate synthase and orotate phosphoribosyltransferase mRNA expressions were higher (p < 0.0001, p <0.0001 respectively in gastric cancer and P = 0.0002, p < 0.0001 respectively in colon cancer) and dihydropyrimidine dehydrogenase mRNA expressions were lower in cancer cells than in cancerous stroma (P = 0.0136 in gastric cancer and p < 0.0001 in colon cancer).
|
18652704 |
2008 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
CTD_human |
Thymidylate synthase messenger RNA expression in plasma from patients with colon cancer: prognostic potential.
|
16609021 |
2006 |
|
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Recently, it has become apparent that rTSb overexpression can cause the downregulation of TS protein in a colon cancer cell line through the production of > or = 1 previously unknown signaling molecules.
|
15929807 |
2005 |
|
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
MSI-H colon cancers showed higher expression of TS compared with MSS (no mutated markers)/MSI-L (one mutated marker) colon cancers (66.6% for MSI-H versus 14.8% MSS/MSI-L; P < 0.0001); 20.8% of MSI-H cases showed high expression of the vascular endothelial growth factor, compared with 45.8% MSS/MSI-L colon cancers (P = 0.0005); 45.8% MSI-H cases had Fp53 compared 11.9% MSS/MSI-L cases (P < 0.0001).
|
15930362 |
2005 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the present study, AQP5 and P-glycoprotein (P-gp), glutathione S-transferase-π (GST-π), topoisomerase II (TOPO II), and thymidylate synthase (TS) were checked in CC and adjacent cancer tissues; AQP5-siRNA was applied to silencing AQP5 in CC cell line HT-29, 5-fluorouracil (5-FU), and cisplatin (DDP) added on cells, and sulforhodamine B (SRB) was used; fluorescence real-time quantitative RT-PCR and Western blot were employed to detect changes in multidrug resistance factor and expression mitogen-activated protein kinase (MAPK) signaling pathway in HT-29.
|
24752576 |
2014 |
|
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Rs7911488 modified the efficacy of capecitabine-based therapy in colon cancer through altering miR-1307-3p and TYMS expression.
|
29088787 |
2017 |
|
Malignant tumor of colon
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Thymidylate synthase polymorphisms and colon cancer: associations with tumor stage, tumor characteristics and survival.
|
17290389 |
2007 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
We have previously shown that miR-215 suppressed the expression of key targets such as thymidylate synthase (TS), dihydrofolate reductase, and denticleless protein homolog (DTL) in colon cancer. miR-215 is a tumor suppressor candidate due to the upregulation of p53 and p21 by targeting DTL.
|
21752725 |
2011 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil.
|
7763285 |
1995 |